1256388-50-7

Basic information

• Product Name: ledipasvir interMediate
• Synonyms: Methyl (S)-1-((S)-6-(5-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-1H-iMidazol-2-yl)-5-azaspiro[2.4]heptan-5-yl)-3-Methyl-1-oxobutan-2-ylcarbaMate;CarbaMic acid, N-[(1S)-1-[[(6S)-6-[5-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-1H-iMidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-Methylpropyl]-, Methyl ester;N-[(1S)-1-[[(6S)-6-[5-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]carbamic acid methyl ester;N-[(1S)-1-[[(6S)-6-[5-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]carbamic acid methyl
• CAS NO: 1256388-50-7
• Molecular Formula: C₂₉H₂₉BrF₂N₄O₃
• Molecular Weight: 599.4663664
• EINECS: -0
• Mol File: 1256388-50-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 789.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.53±0.1 g/cm3(Predicted)
• PKA: 11.13±0.10(Predicted)
• CAS DataBase Reference: ledipasvir interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: ledipasvir interMediate(1256388-50-7)
• EPA Substance Registry System: ledipasvir interMediate(1256388-50-7)

Safety Data

• Hazardous Substances Data: 1256388-50-7(Hazardous Substances Data)

Usage

Description

Ledipasvir intermediate is a chemical compound that serves as a crucial building block in the synthesis of ledipasvir, a medication used to treat chronic hepatitis C infections. This intermediate plays a vital role in the overall chemical synthesis process, with its production involving several chemical reactions and purification steps to ensure purity and quality. Ledipasvir intermediate is an essential component in the pharmaceutical industry, contributing to the development of a medication that has significantly advanced the treatment of hepatitis C infections.

Uses

Used in Pharmaceutical Industry:
Ledipasvir intermediate is used as a key component in the synthesis of ledipasvir, a medication for the treatment of chronic hepatitis C infections. Its role in the production process is critical, as it ensures the purity and quality of the final medication, leading to effective treatment outcomes for patients suffering from this viral infection.

Upstream product

• 1256388-49-4 6-[5-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carboxylic acid benzyl ester 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1229603-71-7 2,7-dibromo-9,9-difluoro-9H-fluorene 
• 14348-75-5 2,7-dibromofluorene-9-one 
• 1256388-48-3 5-aza-spiro[2.4]heptane-5,6-dicarboxylic acid 5-benzyl ester 6-[2-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-oxo-ethyl] ester 
• 111398-44-8 (2R)-2-(methoxycarbonyl amino)-3-methylbutanoic acid 
• 1446396-65-1 2-(L)-methoxycarbonylamino-3-methylbutyric acid 
• 1441670-89-8 (6S)-6-[5-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]heptane-5-carboxylic acid 1,1-dimethylethyl ester 
• 1296797-09-5 C₁₄H₂₂N₂O₅ 

Downstream Products

• 1256388-51-8 methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]-hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 
• 1256393-27-7 3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 

Relevant articles and documents

METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR

Methods of preparing Ledipasvir and derivatives thereof, and intermediate compounds used in the preparation of Ledipasvir are provided. Specifically, a method for preparing the compounds of formula 1 and a series of preparation methods of preparing Ledipasvir are provided. The methods described herein are simple and efficient, and have better application prospects.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.